Kinexum Webcast: Dr. Ralph DeFronzo on the Prevention of T2D

Event Information

Share this event

Date and Time

Event description


Kinexum’s March public webcast features Ralph DeFronzo, MD, Deputy Director of the Texas Diabetes Institute and preeminent authority in the field of diabetes and metabolism. Dr. DeFronzo will speak on "Prevention of Type 2 Diabetes (T2D): A Rational Approach Based on Its Pathophysiology."

1. Log in with your computer to view slides: Click here (no passcode needed).

2. Dial in with your phone for audio: +1 888 601-3595 or +1 304 362-9327.

Please click "Register" to RSVP.

In case of further inquiries, please email

How can type 2 diabetes (T2D) can be targeted in the prediabetes stage?

T2D is preceded by “prediabetes,” and the diagnosis of impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) provides an opportunity for targeted intervention. Prediabetic subjects manifest the two primary core defects characteristic of T2D: insulin resistance and β-cell dysfunction. Interventions that improve insulin sensitivity and/or preserve β-cell function are logical strategies to delay the conversion of IGT/IFG to T2D or revert glucose tolerance to normal.

How can fully manifested T2D can be effectively targeted?

Once T2D becomes fully manifests, at least eight pathophysiologic disturbances contribute to the disturbance in glucose homeostasis. These eight players comprise the Ominous Octet and dictate that:

(1) multiple drugs used in combination will be required to correct the multiple pathophysiologic defects;

(2) treatment should be based on reversal of known pathogenic abnormalities and not simply on reducing A1c; and

(3) therapy must be started early to prevent/slow the progressive β-cell failure that already is well established in IGT subjects.

How can we address the growing issue of T2D?

In this webcast, Dr. DeFronzo will review several lines of diabetes therapy and their effectiveness. Additionally, Dr. DeFronzo will discuss the need for a treatment paradigm shift, specifically combination therapy involving diet/exercise, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a thiazolidinedione (TZD), and a glucagon-like peptide-1 (GLP-1) agonist, to effectively treat, prevent, and even reverse T2D.

About Ralph DeFronzo, MD

Dr. Ralph DeFronzo is a leader in the diabetes field. He is responsible for many of the advances achieved in diabetes over the last 50 years, including developing the concept of insulin resistance, leading the US development of metformin, and discovering a new approach to diabetes treatment that targets glucose reabsorption in the kidneys. His most recent work, along with Dr. Bruno Doiron, has led to a possible cure for diabetes in mice and is being developed for studies in larger animals.

Dr. DeFronzo's major interests focus on the pathogenesis and treatment of T2D and the central role of insulin resistance in the metabolic-cardiovascular cluster of disorders known collectively as the Insulin Resistance Syndrome. Using the euglycemic insulin clamp technique in combination with radioisotope turnover methodology, limb catheterization, indirect calorimetry, and muscle biopsy, he has helped to define the biochemical and molecular disturbances responsible for insulin resistance in T2D.

Dr. DeFronzo graduated from Yale University with a degree in biology and biochemistry, followed by Harvard Medical School with further studies in endocrinology and nephrology. He holds the Joe R. & Teresa Lozano Long Distinguished Chair in Diabetes in the Long School of Medicine at UT Health San Antonio, where he has been on the faculty since 1988. He has received numerous awards, including the Harold Hamm International Prize for Biomedical Research in Diabetes (2017), the Novartis Award at the Annual Scientific Meeting of the American Diabetes Association (ADA) as the outstanding clinical investigator worldwide (2005), and the Albert Renold Award from the ADA for the training of more than 200 young diabetes investigators (2002). He is the author of 750 publications dating back to 1967.

Date and Time

Save This Event

Event Saved